Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs BIOAF


Primary Symbol: V.BTI.H

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > beenthere Responds to My Post
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(64)
•••
Comment by TheTruth1234on Aug 24, 2023 12:10am
94 Views
Post# 35603132

RE:RE:RE:RE:RE:RE:RE:beenthere Responds to My Post

RE:RE:RE:RE:RE:RE:RE:beenthere Responds to My Post
Boomskid wrote: Ohhhhhhhhhhhhhhhhh

Sappy Cap was an example because they're destructive.

Like LT.

I hadn't noticed that LT was destructive.

Well. The share price at .005 might be a clue.

But otherwise, who knew!

You have a flair for the obvious.

jd


Sappy Cap was an example because they're destructive.

Man, for someone who boasts about his readn and studyn the internet abilities,  you sure dont have a clue!


Sabby has also lent struggling Pharmas capital, with extreme over the top conditions. High interest, shares with warrants,  and conditions that are not made public. 


Go and some more readn and studyn Johnny boy.
This is over your head.



Side note - I met with a friend the other day.

The one you tried so hard to discredit,  you know, DC??  The one you lied about and said Bioasis fired him.

While, Johnny boy, I heard he is far from claiming bankruptcy. 

He could retire pretty soon, and guess what???


He HAS a retirement fund!!!!


Where is yours?


Lol.

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities